Whitney Melton
Family · Batesville, ARNPI 1477978054
Payments from drug & device makers
Across 41 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$94
- AbbVie$80
- Boston Scientific$75
- Abbott$55
- Shockwave Medical, Inc$52
- Gilead$46
- plus $375 from 16 others
What the payments were for
- Food & beverage$778100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$778 in reported general payments places this provider in the 60th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 134 | $106,464 |
| OzempicSemaglutide | 74 | $83,993 |
| MounjaroTirzepatide | 52 | $57,226 |
| FarxigaDapagliflozin Propanediol | 60 | $50,711 |
| EntrestoSacubitril/Valsartan | 35 | $38,561 |
| JardianceEmpagliflozin | 39 | $36,905 |
| XareltoRivaroxaban | 36 | $25,222 |
| JanuviaSitagliptin Phosphate | 33 | $24,939 |
| LinzessLinaclotide | 29 | $19,562 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $18,957 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $18,168 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $18,114 |
| GemtesaVibegron | 17 | $10,023 |
| MyrbetriqMirabegron | 14 | $8,980 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $8,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $94 | $106,464134 claims |
| Novo NordiskOzempic | $42 | $83,99374 claims |
| AstraZenecaFarxiga, Symbicort | $46 | $54,63176 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $29 | $42,44250 claims |
| NovartisEntresto | $44 | $38,56135 claims |
| AbbVieLinzess | $80 | $19,56229 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $16 | $10,02317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,103 family providers in Arkansas.
Other family in Batesville
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.